Thus, there is a possibility that mitochondrial protectants shown to improve ALS pathology (such as GNX-4728) may promote their beneficial effects, in part, via inhibition of NLRP3 inflammasome. This evidence concerns the gene NLRP3 and amyotrophic lateral sclerosis.